Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.
about
A review of malaria vaccine clinical projects based on the WHO rainbow tablePreclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxStructure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodiesProduction of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line systemPhase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsTransgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adultsIn vitro growth-inhibitory activity and malaria risk in a cohort study in maliNon-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay.Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.Juxtamembrane shedding of Plasmodium falciparum AMA1 is sequence independent and essential, and helps evade invasion-inhibitory antibodiesThe blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureT cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria.Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunizedSerologic imprint of dengue virus in urban Haiti: characterization of humoral immunity to dengue in infants and young childrenA PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malariaPhase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate--Tackling the Cocktail ChallengeStrain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens.Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?Recent advances in recombinant protein-based malaria vaccines.ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth CohortDemonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development.High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms.Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome.Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1.Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccinesNaturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria.One-step design of a stable variant of the malaria invasion protein RH5 for use as a vaccine immunogen.Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets.Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal 'C-tag'.
P2860
Q21034112-8C24A603-1BD2-4ED6-80BB-B7516477252AQ24273364-298ED5E9-EA9C-461C-B86C-614032F8F26EQ24289322-53D7BF32-A39E-4733-8E1D-FF7C9BFA6F86Q26700012-E2853A0B-2A13-4874-82A3-2E9ACA0F965EQ28731894-38EE3EC0-848D-47D1-AD0A-93B406982421Q28743564-55A5F54C-E776-4FC6-85EB-E5173FB00FF0Q28749215-8A3FBE08-C1AA-4A96-B7D5-B6C472F8AF16Q33613892-D4999574-553E-4B12-B773-D1E239226F8FQ33939405-F4D54EA2-F697-4213-8CFA-1F558BA547D5Q33974904-CD5FFDFF-F55B-4083-9F9E-C3FDB995D957Q34109788-8E09680A-5B45-471A-8457-D194915AA750Q34241973-E7E7E0F6-8FDF-4183-B3E3-667077E5F2FAQ34257253-CFA741D5-5ED4-41FE-BA88-306101F00060Q34416263-D3B4436E-52E4-45FA-853D-A7E2C422A153Q34428497-FA447606-F9DE-4CB8-8021-081E0D9ED76CQ34441098-821C700F-98AD-43F9-B239-45A655AB238BQ34600955-13DFC0F7-6EC7-4510-A06F-B6E0B75B69F9Q34612788-9664EF44-B54A-40D4-BF63-FA46498DF901Q34707858-D1EB9D3C-19C1-497C-BEE3-FDA240F2053DQ34978590-BDB31198-E2EC-490E-91DE-8172AA9DC05AQ35213495-36183485-42D8-4064-A57D-7F345CDED781Q35623459-6604BE7E-6C63-4C81-BEFA-F9302CDC161AQ35683366-5DDA907C-1F4C-4874-8D60-D9108827068CQ36304234-97BFF11E-0C2C-4457-831F-8C7A267E1E30Q36384456-DEE02AA4-B72B-493A-8A3C-635FE4C08D10Q36391845-6DA5BB99-53F9-43FA-9043-BE109DE39C61Q36394182-CC2EEDDA-1D7E-442A-AE65-74949CE87731Q36460499-3A9C75E0-4282-4758-87D2-3906A09B04BCQ36555103-1BEAD4CA-D97D-4685-B8F9-7E33BDBF07C5Q36871970-A5B4555E-F8A3-4B40-BDCA-183183491D7AQ36984161-C24C43D2-3008-47E0-8DE4-0195B64FEEA5Q37352099-B7D07305-158C-4095-BA05-3EAEB6A2ABECQ37496763-3620CFFF-7744-454E-94A5-60984A85BDCDQ37522507-8D0EEF4C-4FFA-46DB-91DB-F72CA13BFFB1Q37530299-0B76F1AD-1A6A-4383-96AD-84B4AC63906BQ37582331-F27D3EE2-7553-4BBD-AE1D-0C07C3DBF0A8Q37626240-D32D7A10-F3D2-4B3C-9C11-15E32E23E282Q37641378-DA35CC5D-932D-4E55-8491-7ED9C75DF3F5Q38096489-A93DE8E0-BC1E-4D99-A5EA-C0156C9ADB90Q38718229-1DB53965-BADF-44E4-83AF-C521BE085135
P2860
Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-apical-membrane-antigen-1 ...... vitro growth inhibition assay.
@en
Anti-apical-membrane-antigen-1 ...... vitro growth inhibition assay.
@nl
type
label
Anti-apical-membrane-antigen-1 ...... vitro growth inhibition assay.
@en
Anti-apical-membrane-antigen-1 ...... vitro growth inhibition assay.
@nl
prefLabel
Anti-apical-membrane-antigen-1 ...... vitro growth inhibition assay.
@en
Anti-apical-membrane-antigen-1 ...... vitro growth inhibition assay.
@nl
P2093
P2860
P50
P356
P1476
Anti-apical-membrane-antigen-1 ...... vitro growth inhibition assay.
@en
P2093
Ababacar Diouf
Gregory E D Mullen
Laura B Martin
Mark A Pierce
Samuel E Moretz
P2860
P304
P356
10.1128/CVI.00042-09
P577
2009-05-13T00:00:00Z